TargetBeta
ERBB2
erb-b2 receptor tyrosine kinase 2 · also NEU, HER-2, CD340, HER2 · CD molecules
37 programs in company-led studies act on ERBB2, from 28 companies: 22 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (21 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Breast Neoplasms, 29 programs
- Carcinoma, Non-Small-Cell Lung, 13 programs
- Stomach Neoplasms, 10 programs
- Colorectal Neoplasms, 9 programs
- Ovarian Neoplasms, 4 programs
- Endometrial Neoplasms, 3 programs
- Neoplasm Metastasis, 3 programs
- Neoplasms, 3 programs
- Prostatic Neoplasms, 3 programs
- Biliary Tract Neoplasms, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026trastuzumab botidotin · Sichuan Kelun Pharmaceutical · phase 3 · NCT06968585
- Dec 2026trastuzumab rezetecan · Jiangsu HengRui Medicine · phase 3 · NCT06840002
- Dec 2026disitamab vedotin · RemeGen · phase 3 · NCT06221748
- Dec 2026trastuzumab brengitecan · Sichuan Biokin Pharmaceutical · phase 3 · NCT06114511
- Dec 2026Lutetium-177 · Novartis · phase 3 · NCT05884255
- Dec 2026Anti-HER2 Bispecific Antibody TQB2930 · Sino Biopharmaceutical · phase 3 · NCT06202261
- Dec 2026Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705 · 3SBio · phase 2 · NCT06390774
- Dec 2026enozertinib · ORIC Pharmaceuticals · phase 2 · NCT06816992
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.